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Transcatheter Closure of Ventricular Septal Defect
and Atrial Septal DefectLeft-to-right shunt lesions account for more than 50% of
congenital heart disease (CHD). Ventricular septal defect
(VSD) is the most common CHD accounting for 30% of CHD1
and atrial septal defect (ASD) accounts for 6e10% of CHD.
Perimembranous-type VSD accounts for 70e80% of VSD,
whereas muscular-type VSD accounts for 10e15% of VSD.
Muscular trabecular-type VSD may be present transiently in
newborns and young infants and undergo spontaneous
closure as patients grow up.2 Spontaneous closure may also
occur in perimembranous-type VSD and continue to take
place during childhood, adolescence, and adulthood. The
natural history of VSD should be considered when treat-
ment is being planned. In the presence of symptoms such as
hemodynamic significant shunt or cardiomegaly, closure of
VSD should be performed. Surgery is the conventional
modality for closure of VSD. Since the first report of
transcatheter closure of VSD in 1988, transcatheter closure
of VSD has been increasingly performed.3 Amplatzer
muscular VSD occluder (AGA medical, Plymouth, MN, USA),
approved by Food and Drug Administration, has been usedFigure 1 (A) A case of Tetralogy of Fallot status post-total re
observed. (B) A muscular VSD occluder was deployed with small re
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results (Figure 1).4 The hybrid procedure has been devel-
oped to close large muscular-type VSD in infants with heart
failure where surgical closure is difficult. An AGA muscular
VSD device was implanted via perventricular route after
sternotomy. In a clinical trial of original type of Amplatzer
perimembranous VSD occluder, persistent complete heart
block occurred in around 3e5% of patients, which is much
higher than that in surgery.5e7 Therefore, its clinical
application was not approved by Food and Drug Adminis-
tration. Recently, modifications of the Amplatzer peri-
membranous VSD device were made to minimize the
possibility of complete heart block and increase the success
rate. Several studies have proved the safety and efficiency
in using symmetric as well as asymmetric VSD occluders in
the closure of perimembranous VSD.8e10 The reported
incidence of complete heart block was around 1.5%, which
was comparable with that of surgery. It is suggested that
the device diameter should be less than 1.8 mm larger than
VSD to avoid complete heart block. Recently, Nit occludpair, large muscular ventricular septal defects (VSDs) were
sidual shunt.
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to close perimembranous VSD with low complication rate.11
Echocardiographic monitoring during the procedure is
crucial to procedural success. Both transesophageal echo-
cardiography and transthoracic echocardiography are
useful in monitoring the procedure. Muscular trabecular
VSD as well as perimembranous VSD can now be safely and
effectively closed with transcatheter technique. Despite
these advancements in catheter closure of VSD, infants or
young children weighing less than 10 kg with large peri-
membranous VSD should receive surgery.8
Spontaneous closure or decrease in size may also occur in
secundum-type ASD, but this occurs mostly in young chil-
dren.12 Some ASDs can enlarge over time. Catheter closure
of ASD is indicated in patients with symptoms such as right
heart volume overload or pulmonary-to-systemic flow ratio
above 1.5. Because the symptoms of ASD are frequently
subtle, ASD may be undetected until symptoms occur.
Therefore, ASD is the most common CHD found in adulthood.
Many adults with unrepaired ASD developed arrhythmia,
heart failure, and pulmonary hypertension.13,14 Patients
with Eisenmenger syndrome should be excluded for cath-
eter closure. Amplatzer septal occluder has been used in
the closure of secundum-type ASD for more than 10 years
with a high success rate and low complication rate.15e17
Transesophageal echocardiography or intracardiac echo-
cardiography were generally used to monitor the proce-
dure. The major complications of catheter closure of ASD
were embolization of device, heart block, and cardiac
erosion. Embolization of device occurs in around 0.5e1%
procedures. Transcatheter retrieval of migrated devices is
possible but many of them required emergent surgery to
retrieve the device and repair the defect. Complete heart
block occurs rarely. Cardiac erosion, which is a life
threatening complication, occurs in around 0.1% proce-
dures.16 Use of a excessively oversized device has been
incriminated for the development of this catastrophic
event. New-onset atrial arrhythmia is not rare in adults
following catheter closure of ASD but most of the new-
onset arrhythmias are self-limited. Minor complications,
including migraine and transient elevation in Troponin I,
were reported. In a recent study, Troponin I level after
catheter closure of ASD was significantly correlated with
the ratio of device size to body surface area.18 Because of
high success rate and low complication rate of catheter
closure of ASD, surgery should be reserved for those in
whom catheter closure was not successful.
There are advantages of catheter interventions over
surgery, including avoidance of scar, transfusion, and
cardiopulmonary bypass. Hospitalization and rehabilitation
time were shortened. Despite this, catheter closure of
intracardiac shunts carries potential risks. Care should
be taken to avoid the major complications of catheter
interventions.
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